Debt to Capital Ratio: A measurement of a company's financial leverage, calculated as the company's long-term debt divided by its total capital. Calculated as: Total Long-Term Debt / (Total Long-Term Debt + Shareholders Equity)
BridgeBio Pharma, Inc. (BBIO) had Debt to Capital Ratio of 25.84 for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$110.56M |
|
$-181.90M |
|
$3.65M |
|
$106.91M |
|
$244.84M |
|
$-134.28M |
|
$-47.38M |
|
$-181.66M |
|
$-181.66M |
|
$-183.76M |
|
$-183.76M |
|
$-183.76M |
|
$-183.76M |
|
$-134.28M |
|
$-132.96M |
|
190.52M |
|
190.52M |
|
$-0.95 |
|
$-0.95 |
|
| Balance Sheet Financials | |
$912.28M |
|
$6.11M |
|
$167.91M |
|
$1.08B |
|
$175.85M |
|
$1.85B |
|
$2.68B |
|
$2.86B |
|
$-1.78B |
|
$-1.81B |
|
$-1.78B |
|
191.16M |
|
| Cash Flow Statement Financials | |
$-279.92M |
|
$-14.60M |
|
$362.37M |
|
$683.24M |
|
$751.10M |
|
$67.86M |
|
$63.12M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.19 |
|
-- |
|
-- |
|
|
Debt to Capital Ratio |
25.84 |
-1.04 |
|
96.70% |
|
-121.45% |
|
-121.45% |
|
-- |
|
-164.30% |
|
-164.52% |
|
$-280.51M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
0.20 |
|
1.44 |
|
62.57 |
|
10.34% |
|
10.17% |
|
-17.01% |
|
-256.70% |
|
$-9.30 |
|
$-1.47 |
|
$-1.47 |
|